A citation-based method for searching scientific literature

Felix C Saalfeld, Carina Wenzel, Petros Christopoulos, Sabine Merkelbach-Bruse, Timm M Reissig, Silke Laßmann, Sebastian Thiel, Jan A Stratmann, Ralf Marienfeld, Johannes Berger, Alexander Desuki, Janna-Lisa Velthaus, Diego Kauffmann-Guerrero, Albrecht Stenzinger, Sebastian Michels, Thomas Herold, Michael Kramer, Sylvia Herold, Amanda Tufman, Sonja Loges, Jürgen Alt, Maria Joosten, Gerlinde Schmidtke-Schrezenmeier, Martin Sebastian, Susann Stephan-Falkenau, Cornelius F Waller, Marcel Wiesweg, Jürgen Wolf, Michael Thomas, Daniela E Aust, Martin Wermke. J Thorac Oncol 2021
Times Cited: 6







List of co-cited articles
68 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
345
83

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy,[...]. J Thorac Oncol 2020
84
83

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper,[...]. Cancer Discov 2020
91
66

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Sally C M Lau, Aline Fusco Fares, Lisa W Le, Kate M Mackay, Spencer Soberano, Sze Wah Chan, Elliot Smith, Malcolm Ryan, Ming Sound Tsao, Penelope A Bradbury,[...]. Clin Lung Cancer 2021
16
66

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
Caicun Zhou, Xingya Li, Qiming Wang, Guanghui Gao, Yiping Zhang, Jianhua Chen, Yongqian Shu, Yanping Hu, Yun Fan, Jian Fang,[...]. J Clin Oncol 2020
47
66

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Bob T Li, Ronglai Shen, Darren Buonocore, Zachary T Olah, Ai Ni, Michelle S Ginsberg, Gary A Ulaner, Michael Offin, Daniel Feldman, Todd Hembrough,[...]. J Clin Oncol 2018
196
66

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Solange Peters, Rolf Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M Kowalski, Christina S Baik, Dolores Isla, Javier De Castro Carpeno, Pilar Garrido,[...]. Clin Cancer Res 2019
90
50

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
J Mazières, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, S Peters, E Dansin, M Früh, M Pless,[...]. Ann Oncol 2016
182
50

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Hisayuki Shigematsu, Takao Takahashi, Masaharu Nomura, Kuntal Majmudar, Makoto Suzuki, Huei Lee, Ignacio I Wistuba, Kwun M Fong, Shinichi Toyooka, Nobuyoshi Shimizu,[...]. Cancer Res 2005
503
50

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Maria E Arcila, Jamie E Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K Paik, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
280
50

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.
Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, Mehmet Altan, Don L Gibbons, Frank V Fossella, Vincent K Lam, Anisha B Patel, Marcelo V Negrao, Xiuning Le,[...]. J Clin Oncol 2022
7
50

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
Kiichiro Ninomiya, Tae Hata, Hiroshige Yoshioka, Kadoaki Ohashi, Akihiro Bessho, Shinobu Hosokawa, Nobuhisa Ishikawa, Masahiro Yamasaki, Takuo Shibayama, Keisuke Aoe,[...]. Chest 2019
17
50

HER2-targeted therapies - a role beyond breast cancer.
Do-Youn Oh, Yung-Jue Bang. Nat Rev Clin Oncol 2020
196
50

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Bob T Li, Egbert F Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas N Saltos, Enriqueta Felip,[...]. N Engl J Med 2022
30
50

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang,[...]. Oncologist 2019
16
50

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang,[...]. Oncologist 2020
16
50

Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Kaiyan Chen, Guoqiang Pan, Guoping Cheng, Fanrong Zhang, Yanjun Xu, Zhiyu Huang, Yun Fan. Thorac Cancer 2021
17
50

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Alessandro Leonetti, Sugandhi Sharma, Roberta Minari, Paola Perego, Elisa Giovannetti, Marcello Tiseo. Br J Cancer 2019
271
33

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren,[...]. Lancet Oncol 2011
33

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Rathi N Pillai, Madhusmita Behera, Lynne D Berry, Mike R Rossi, Mark G Kris, Bruce E Johnson, Paul A Bunn, Suresh S Ramalingam, Fadlo R Khuri. Cancer 2017
81
33

Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Philip Stephens, Chris Hunter, Graham Bignell, Sarah Edkins, Helen Davies, Jon Teague, Claire Stevens, Sarah O'Meara, Raffaella Smith, Adrian Parker,[...]. Nature 2004
591
33


Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla,[...]. Eur J Cancer 2021
16
33

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Juliann Chmielecki, Jeffrey S Ross, Kai Wang, Garrett M Frampton, Gary A Palmer, Siraj M Ali, Norma Palma, Deborah Morosini, Vincent A Miller, Roman Yelensky,[...]. Oncologist 2015
51
33


Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Takayuki Kosaka, Junko Tanizaki, Raymond M Paranal, Hideki Endoh, Christine Lydon, Marzia Capelletti, Claire E Repellin, Jihyun Choi, Atsuko Ogino, Antonio Calles,[...]. Cancer Res 2017
79
33

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
Adriana Estrada-Bernal, Anh T Le, Andrea E Doak, Vijaya G Tirunagaru, Shevan Silva, Matthew R Bull, Jeff B Smaill, Adam V Patterson, Chul Kim, Stephen V Liu,[...]. Clin Cancer Res 2021
24
33

Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.
Han Han, Shuai Li, Ting Chen, Michael Fitzgerald, Shengwu Liu, Chengwei Peng, Kwan Ho Tang, Shougen Cao, Johara Chouitar, Jiansheng Wu,[...]. Cancer Res 2021
5
40

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang, C Rivard, G Gao, T L Ng, M M Tu,[...]. Ann Oncol 2019
93
33

HER2 expression status in diverse cancers: review of results from 37,992 patients.
Min Yan, Maria Schwaederle, David Arguello, Sherri Z Millis, Zoran Gatalica, Razelle Kurzrock. Cancer Metastasis Rev 2015
186
33

High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.
Masaaki Nagano, Shinji Kohsaka, Toshihide Ueno, Shinya Kojima, Kanju Saka, Hirotaro Iwase, Masahito Kawazu, Hiroyuki Mano. Clin Cancer Res 2018
33
33

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim,[...]. Cancer Res Treat 2018
41
33

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Jacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, Brett W Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal,[...]. Nat Med 2018
201
33


Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, Lisa M Crocker, Kathryn L Parsons, Elaine Mai, Walter A Blättler, John M Lambert, Ravi V J Chari, Robert J Lutz,[...]. Cancer Res 2008
33

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis.
Kadoaki Ohashi, Kiichiro Ninomiya, Hiroshige Yoshioka, Akihiro Bessho, Takuo Shibayama, Keisuke Aoe, Nobuhisa Ishikawa, Toshiyuki Kozuki, Haruyuki Kawai, Shoichi Kuyama,[...]. Lung Cancer 2020
3
66

Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Yun Fan, Jianhua Chen, Chengzhi Zhou, Huijuan Wang, Yongqian Shu, Jacky Zhang, Hairui Hua, Dennis Chin-Lun Huang, Caicun Zhou. Lung Cancer 2020
8
33

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M Clarke, Nishan Tchekmedyian, Jonathan W Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V Heymach,[...]. J Clin Oncol 2022
4
50

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
U Gatzemeier, G Groth, C Butts, N Van Zandwijk, F Shepherd, A Ardizzoni, C Barton, P Ghahramani, V Hirsh. Ann Oncol 2004
264
33

Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.
Hiromasa Yamamoto, Koichiro Higasa, Masakiyo Sakaguchi, Kazuhiko Shien, Junichi Soh, Koichi Ichimura, Masashi Furukawa, Shinsuke Hashida, Kazunori Tsukuda, Nagio Takigawa,[...]. J Natl Cancer Inst 2014
77
33

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
Bob T Li, Dara S Ross, Dara L Aisner, Jamie E Chaft, Meier Hsu, Severine L Kako, Mark G Kris, Marileila Varella-Garcia, Maria E Arcila. J Thorac Oncol 2016
134
33

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, Monique B Nilsson, Lemei Hu, Junqin He, Fahao Zhang, Marlese Pisegna, Alissa Poteete, Huiying Sun,[...]. Cancer Cell 2019
65
33

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Marcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bara, Vincent Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y Elamin,[...]. J Immunother Cancer 2021
10
33

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
Natalia Jura, Yibing Shan, Xiaoxian Cao, David E Shaw, John Kuriyan. Proc Natl Acad Sci U S A 2009
224
33

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Bob T Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai-Yan Tu, Mackenzie L Myers, Chongrui Xu,[...]. Cancer Discov 2020
57
33

Targeted therapy in NSCLC driven by HER2 insertions.
Solange Peters, Stefan Zimmermann. Transl Lung Cancer Res 2014
45
33

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
33

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
F R Hirsch, M Varella-Garcia, W A Franklin, R Veve, L Chen, B Helfrich, C Zeng, A Baron, P A Bunn. Br J Cancer 2002
173
33

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.
Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian Rolfo, Alfredo Addeo. Nat Rev Clin Oncol 2022
8
33

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Heidi Greulich, Bethany Kaplan, Philipp Mertins, Tzu-Hsiu Chen, Kumiko E Tanaka, Cai-Hong Yun, Xiaohong Zhang, Se-Hoon Lee, Jeonghee Cho, Lauren Ambrogio,[...]. Proc Natl Acad Sci U S A 2012
191
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.